Reduction of incretin-like salivatin in saliva from patients with type 2 diabetes and in parotid glands of streptozotocin-diabetic BALB/c mice
| Autor: | M. Kobayashi, T. Sasamura, H. Sasamoto, S. Ohgaku, Y. Sugihara, I. Kimura |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Saliva
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Incretin Type 2 diabetes medicine.disease Streptozotocin Glucagon Glucagon-like peptide-1 Endocrinology stomatognathic system Internal medicine Diabetes mellitus Internal Medicine medicine business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 3:254-258 |
| ISSN: | 1462-8902 |
| DOI: | 10.1046/j.1463-1326.2001.00118.x |
| Popis: | SUMMARY Aim Diabetic xerostomia is a typical syndrome in diabetic complication. We have reported that salivatin (salivary peptide P-C) derived from human saliva potentiates glucose-stimulated insulin release and inhibits arginine-stimulated glucagon release. The present study is aimed to gain further evidence on the physiological role by investigating the diabetic state-induced change in the amount of salivatin. Methods The amount of salivatin was measured in saliva taken from patients with type 2 diabetes with ELISA and with rabbit antiserum against human salivatin immunocytochemically in sections of parotid glands from streptozotocin-diabetic BALB/c mice. Results The amount of salivatin after a meal was reduced by diabetes in both human saliva and in the serous secretory granule of mouse parotid gland acinar cells. Conclusions The above results suggest that salivatin lowers hyperglycaemia after meal and sustains the normal blood glucose levels by incretin-like mechanisms. The function may be damaged by diabetes, and this in turn might make the diabetes worse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text